These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 17994386)

  • 21. Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients.
    Huang YC; Chang JS; Wu KH; Peng CT
    Hemoglobin; 2006; 30(2):229-38. PubMed ID: 16798648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deferiprone: second-line treatment of iron overload in the absence of a better alternative.
    Prescrire Int; 2007 Oct; 16(91):196. PubMed ID: 17926834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia.
    Mazza P; Amurri B; Lazzari G; Masi C; Palazzo G; Spartera MA; Giua R; Sebastio AM; Suma V; De Marco S; Semeraro F; Moscogiuri R
    Haematologica; 1998 Jun; 83(6):496-501. PubMed ID: 9676021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nephrolithiasis in beta thalassemia major patients treated with deferasirox: an advent or an adverse event? A single Greek center experience.
    Efthimia V; Neokleous N; Agapidou A; Economou M; Vetsiou E; Teli A; Perifanis V
    Ann Hematol; 2013 Jan; 92(2):263-5. PubMed ID: 22933235
    [No Abstract]   [Full Text] [Related]  

  • 25. Deferiprone: new preparation. Poorly assessed.
    Prescrire Int; 2000 Oct; 9(49):131-5. PubMed ID: 11603411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Agranulocytosis in a patient with thalassaemia major during treatment with the oral iron chelator, 1,2-dimethyl-3-hydroxypyrid-4-one.
    al-Refaie FN; Veys PA; Wilkes S; Wonke B; Hoffbrand AV
    Acta Haematol; 1993; 89(2):86-90. PubMed ID: 8503250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe Henoch-Schönlein purpura in a thalassemic patient under deferiprone treatment.
    Unal S; Gücer S; Kale G; Besbas N; Ozen S; Gümrük F
    Am J Hematol; 2008 Feb; 83(2):165-6. PubMed ID: 17712793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deferiprone-associated myelotoxicity.
    al-Refaie FN; Wonke B; Hoffbrand AV
    Eur J Haematol; 1994 Nov; 53(5):298-301. PubMed ID: 7813710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety profile of the oral iron chelator deferiprone: a multicentre study.
    Cohen AR; Galanello R; Piga A; Dipalma A; Vullo C; Tricta F
    Br J Haematol; 2000 Feb; 108(2):305-12. PubMed ID: 10691860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful recovery of acute hemosiderotic heart failure in beta-thalassemia major treated with a combined regimen of desferrioxamine and deferiprone.
    Tavecchia L; Masera N; Russo P; Cirò A; Vincenzi A; Vimercati C; Masera G
    Haematologica; 2006 Jun; 91(6 Suppl):ECR19. PubMed ID: 16785138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators.
    al-Refaie FN; Hershko C; Hoffbrand AV; Kosaryan M; Olivieri NF; Tondury P; Wonke B
    Br J Haematol; 1995 Sep; 91(1):224-9. PubMed ID: 7577638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and adverse effects of oral iron chelator deferiprone (l1, 1,2- dimethyl-3-hydroxypyrid-4-one) in patients with beta thalassaemia major in Pakistan.
    Ayyub M; Ali W; Anwar M; Waqar A; Khan MN; Ijaz A; Hussain T; Hussain S
    J Ayub Med Coll Abbottabad; 2005; 17(4):12-5. PubMed ID: 16599026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of combined deferiprone and desferrioxamine iron chelating therapy in beta-thalassemia major end-stage heart failure: a case report.
    Porcu M; Landis N; Salis S; Corda M; Orrù P; Serra E; Usai B; Matta G; Galanello R
    Eur J Heart Fail; 2007 Mar; 9(3):320-2. PubMed ID: 17029959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload.
    ElAlfy MS; Sari TT; Lee CL; Tricta F; El-Beshlawy A
    J Pediatr Hematol Oncol; 2010 Nov; 32(8):601-5. PubMed ID: 20921906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deferiprone-induced agranulocytosis: 20 years of clinical observations.
    Tricta F; Uetrecht J; Galanello R; Connelly J; Rozova A; Spino M; Palmblad J
    Am J Hematol; 2016 Oct; 91(10):1026-31. PubMed ID: 27415835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
    Kattamis A; Kassou C; Berdousi H; Ladis V; Papassotiriou I; Kattamis C
    Haematologica; 2003 Dec; 88(12):1423-5. PubMed ID: 14687998
    [No Abstract]   [Full Text] [Related]  

  • 38. Deferiprone for thalassemia major.
    Rajeshwari K
    Indian Pediatr; 1999 Jul; 36(7):738-40. PubMed ID: 11203460
    [No Abstract]   [Full Text] [Related]  

  • 39. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M; Carrara P; Pinto V; Forni GL
    Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
    [No Abstract]   [Full Text] [Related]  

  • 40. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
    Economou M; Printza N; Teli A; Tzimouli V; Tsatra I; Papachristou F; Athanassiou-Metaxa M
    Acta Haematol; 2010; 123(3):148-52. PubMed ID: 20185899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.